secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2022-06-22T23:59:59+00:00
Accession:  0000950170-22-011935
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Phase 2 ACT-AD misses primary endpoint; monotherapy subgroup shows cognitive benefit
--------------------------------------------------------------------------------

- Primary endpoint ERP P300 latency not statistically significant in full mITT population (-6.02 ms vs placebo).
- Pre-specified subgroup: combination with AChEIs diminished fosgonimeton effect; post hoc monotherapy showed ERP P300 improvement of -28 ms and ADAS-Cog11 -3.3 points.
- Fosgonimeton well tolerated; no treatment-related SAEs or deaths; injection site reaction most common AE.
- Study enrolled 77 patients; 14% early termination rate; results to inform ongoing Phase 3 LIFT-AD (NCT04488419).
- Management plans to seek regulatory advice on potential adaptations to LIFT-AD based on these findings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022011935/0000950170-22-011935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022011935/atha-20220622.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer